Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment*. (12th November 2013)

• Record Type: Journal Article
• Authors: Puig, Lluís; Strohal, Robert; Fuiman, Joanne; Pedersen, Ronald; Szumski, Annette; Koenig, Andrew S.; Robertson, Deborah; Drexel, Heinz
• Is Part Of: Journal of dermatological treatment. Volume 25:Number 6(2014:Dec.)
• Page Start: 470
• Page End: 481
• Publication Date: 2013-11-12
• Subjects: cardiovascular risk -- comorbidities -- etanercept -- metabolic syndrome -- psoriasis -- treatment; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.3109/09546634.2013.848260
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Objective : To assess cardiometabolic biomarkers in patients with psoriasis before and after etanercept treatment. Methods : Patients with moderate-to-severe plaque psoriasis were randomized to etanercept 50 mg once or twice weekly, double-blinded. Cardiometabolic biomarkers were assessed at baseline and after 12 weeks of treatment ( n = 273). Results : At baseline, 42% of patients had metabolic syndrome. Etanercept was not associated with any clinically relevant adverse effects on cardiometabolic biomarkers. In the once-weekly subgroup, significant mean percentage changes from baseline ( p < 0.05) were observed for the quantitative insulin-sensitivity check index (QUICKI; −2.2%), apolipoprotein (Apo) A1 (3.2%), Apo B:Apo A1 ratio (−3.5%), leptin (8.6%) and high-sensitivity C-reactive protein (hsCRP) (−65.5%); and in the twice-weekly subgroup for plasma insulin (15.9%), QUICKI (−2.7%), high-density lipoprotein cholesterol (HDL-C; 2.9%), apolipoprotein (Apo) A1 (2.8%), Apo B:Apo A1 (−4.6%) and hsCRP (−74.4%). Conclusion : Metabolic syndrome was common in these patients with moderate-to-severe psoriasis. Etanercept treatment may provide some potentially favorable modulation of insulin sensitivity, HDL-C, Apo A1 and Apo B:Apo A1 ratio.